Programme Supplement [International Conference on AIDS (16th: 2006: Toronto, Canada)]

Thursday 17 August
Late Breaker Abstracts:45- 15:45

THLBO2 Late Breaker Track B

Abst

ion

Venue:
Date:
Time:
Chairs:

Session Room 1, Level 800
Thursday 17 August
12:45 - 15:45
tedro Cahn, Argentina
Sharon Walmsley, Canada
Andrew Zolopa, United States
Elly Katabira, Uganda

FR ES RU

13:35
THLBO206
13:45
THLBO207
13:55

12:45
THLBO201 A two-year randomized controlled
clinical trial in antiretroviral-nailve
subjects using lopinavir/ritonavir
(LPV/r) monotherapy after initial
induction treatment compared to an
efavirenz (EFV) 3-drug regimen (Study
M03-613)
W. Cameron', B. da Silva2, J. Arribas3, R.
Myers2, N. Bellos2, N. Gilmore', K. Niemi, K.
Wikstrom2, M. King2, G. Hanna2, S. Brun2
'Canada, 2United States, 3Spain

12:55
THLB0202
13:05

MONARK Trial (MONotherapy
AntiRetroviral Kaletra): 48-Week
Analysis of Lopinavir/Ritonavir
(LPV/r) Monotherapy compared to LPV/r
+ Zidovudine/Lamivudine (AZT/3TC) in
Antiretroviral-Nailve Patients
J.-F. Delfraissy', P. Flandre', C. Delaugerre',
A. Horban2, P.-M. Girard', C. Rouziouxl, M.
Norton3, I. Cohen-Codar', P. NgoVan, J. -P.
Chauvin'
'France, 2Poland, 3United States

14:05
THLBO209
14:15
THLBO210
14:25
THLBO211
14:35
THLBO212

Improving HIV Screening with Rapid
Testing and Streamlined Counseling
H. Anaya, S. Asch
United States
A structured treatment interruption
(STI) strategy of 12 week cycles on and
off ART is clinically inferior to continuous
treatment in patients with low CD4
counts before ART: a randomisation
within the DART trial
J./ Hakim, on behalf of the DART Trial Team
[TBC]
Zimbabwe,
Survival and Causes of Death, 2 years
after introduction of Antiretroviral
Therapy in Africa: a historical cohort
comparison in Entebbe, Uganda
P. Munderi/', C. Wateral, J. Nakiyingi', A.
Kasirye', S. Walker2, N. French2, C. Gilks3, H.
Grosskurth
'Uganda, 2United Kingdom, 3Switzerland
Rapid expansion of the national
antiretroviral treatment program in
Thailand: program outcomes and patient
survival, 2000-2005
P. Ningsanond, C. Lertpiriyasuwat, M.
McConnell, S. Chasombat, U. Siangphoe, P.
Mock, K. Fox, S. Thanprasertsuk
Thailand
High Prevalente and Mortality from
Extensively-Drug Resistant (XDR) TB
in TB/HIV Coinfected Patients in Rural
South Africa
N.R. Gandhi', A. MolP2, R. Pawinski2, A. W.
Sturm2, U. Lall//oo2, K. Zell//er', J. Andrews', G.
Friedland'
'United States, 2South Africa
Efavirenz (EFV)-based regimens are
potent in treatment-naive subjects
across a wide range of pre-treatment
HIV-1 RNA (VL) and CD4 cell counts: 3 -year results from ACTG 5095 (A5095)
H. Ribaudo, D. Kuritzkes, C. Lalama, J.
Schouten, B. Schackman, R. Gulick, AIDS
Clinical Trials Group
United States,
Recombinant human growth hormone
(r-hGH) to treat HIV-associated Adipose
Redistribution Syndrome (HARS):
12-week (Wk) induction and 24-wk
maintenance therapy (Tx)
C. Grunfeld, M. Thompson, S.J. Brown, G.
Richmond, D.A. Lee, N. Muurahainen, D.P.
Kotler, and the Study 24380 Investigators
Group
United States,

Thursday

THL

LB0203 Lopinavir/ritonavir as single-drug
maintenance therapy in patients with
HIV-1 viral suppression: Forty eight
week results of a randomized, controlled,
open label, clinical trial (OK04 Study)
J. Arribas', F. Pulido', R. Delgado', E.
Cabrero', C. Cepeda', J. Gonzalez-Garcia',
M.J. Perez-Elias', A. Arranz', J. Portilla',
J. Pasquau', J.A. Iribarren', R. Rubio', A.
Ocampo', P. Miralles', H. KnobePl', F. Gaya',
R. Mufoz', M. Norton2, OK04 Study Group
'Spain, 2United States,

Inde

13:15
THLBO204
13:25
THLBO205

A prospective, randomized, Phase III
trial of NRTI-, PI-, and NNRTI-sparing
regimens for initial treatment of HIV-1
infection - ACTG 5142
S.A. Riddler', R. Haubrich', G. DiRienzo', L.
Peeples', W.G. Powderly2, K.L. Klingman',
K.W. Garren', T. George', J.F. Rooney', B.
Brizz', D. Hav/ir', J. W. Mell//ors', AIDS Clinical
Trials Group 5142 Study Team
'United States, 2Ireland,
The KLEAN Study: Fosamprenavir +
ritonavir (FPV/r) versus lopinavir/
ritonavir (LPV/r) in antiretroviral-naive
(ART-Naive) HIV-1 infected adults over
48 weeks
J. Eron', P. Yeni2, J. Gathe, Jr.', V.
Estrada3, E. DeJesus', S. Staszewski4, P.
Lackey', L. Yau', D. Sutherland-Phillips', P.
Wannamaker', M. Shaefer'
'United States, 2France, 3Spain, 4Germany

XVI INTERNATIONAL AIDS CONFERENCE * 13-18 AUGUST'2006 * TORONTO CANADA * PROGRAMME SUPPLEMENT